The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33928630/
doi: 10.1111/bjh.17460. Online ahead of print. 1 Vanderbilt University Medical Center, Nashville, TN, USA. 2 Peking University Institute of Hematology, Beijing, China. 3 Chaim Sheba Medical Center, Tel Hashomer, Israel,...
-
Mark Fesler4yrEven though some indications have rather short followup, it is likely that car t will lessen the use of alloSCT for the NHL indications it’s approved for
EGR1 addiction in diffuse large B cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33980611/
Early growth response gene (EGR1) is a transcription factor known to be a downstream effector of B cell receptor signaling and Janus kinase 1 (JAK1) signaling in diffuse large B...
-
Mark Fesler4yrThis is an interesting article describing the potentially vital role efr1 plays in disruption of this factor will lead to improved outcomes
Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33981851/
Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients' age....
-
Mark Fesler4yrThis is not surprising data given the degree and duration of lymphopenia induced by bendamustine. Caution with this agent in the covid and car T era
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34012442/
Adoptive immunotherapy using chimeric antigen receptor (CAR)-T cells has achieved successful remissions in refractory B-cell leukemia and B-cell lymphomas. In order to estimate both success and severe side effects of...
-
Mark Fesler4yrThis is very important work that will not only lead to better prognostication and prediction with car T therapy but also lead to commercially available assays for current constructs
Lenalidomide in DLBCL: are we past the cell of origin? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33989279/
Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant. However, the addition...
-
Mark Fesler4yrA nice review on an important drug in Dlbcl in spite of some negative trials. The ability of this agent to induce and maintain very prolonged responses makes it Show More